Adoptive immunotherapy in postoperative hepatocellular carcinoma: A systemic review

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Xie, Feng ^a   Zhang, Xinji ^a   Li, Hui ^a   Zheng, Tao ^a   Xu, Feng ^a   Shen, Rongxi ^a   Yan, Long ^a   Yang, Jiamei ^a   He, Jia ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; RADICAL RESECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SURVIVAL ANALYSIS;

EID: 84865055267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042879     Document Type: Review

References (28)

1. de Visser K, Coussens L, (2006) The Inflammatory Tumor Microenvironment and Its Impact on Cancer Development. Contributions to Microbiology 13: 118-137.
2. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, et al. (2002) Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 17: 889-896.
3. Chang HH, Hsieh KY, Yeh CH, Tu YP, Sheu F, et al. (2010) Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma. Int Immunopharmacol 10: 239-46.
4. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA, (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Journal of Experimental Medicine 155: 1823-1841.
5. dt-Wolf, Negrin RS, Kiem H-P, Blume KG, Weissman IL, et al. (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. Journal of Experimental Medicine 174: 139-149.
6. Tan A, Aucejo F, Kim R, (2010) Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma? Oncology 78: 161-71.
7. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, et al. (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807.
8. Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, et al. (1995) Adjuvant chemoimmunotherapy forhepatocellular carcinoma patients:Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycinalone. Am J Clin Oncol 18: 257-262.
9. Jadad AR, Moore RA, Carroll D, (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1): 1-12.
10. Llovet JM, Bruix J, (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442.
11. Deeks JJ, Higgins JPT, Altman DG (2008) Chapter 9: Analyzing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from http://www.cochrane-handbook.org.
12. Cochran WG, (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
13. Higgins JPT, Thompson SG, (2002) Quantifying heterogeneity in a metaanalysis. Stat Med 21: 1539-1558.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. British Medical Journal 327: 557-560.
15. Zhou Weiping, Wu Mengchao, Yao Xiaoping, Yang Jiamei, (2002) The Effects of Combined Hepatectomy and Immunochemotherapy on Postoperative Recurrence of Primary Liver Cancer. The Chinese-German JournaI of Clinical Oncology 1: 163-165.
16. Xie L, Pang R, Jin Y, Xiang S, Li H, et al. (2000) Effects of hepatic artery chemotherapeuticembolization combined with perfusing LAKcells into hepatic artery after radicaloperation of liver cancer. Zhonghua Gan Zang Bing Za Zhi 8: 142-143.
17. Lu Bing, Li Deyu, Zhang Xiao, (2008) Clinical studies on effects of CIK in patients of postoperative hepatocellular carcinoma. Journal of Medical Forum 29: 69-70.
18. Hui D, Qiang L, Jian W, Ti Z, Da-Lu K, et al. (2009) A randomized, controlled trial ofpostoperative adjuvant cytokine-inducedkiller cells immunotherapy after radicalresection of hepatocellular carcinoma. Dig Liver Dis 41: 36-41.
19. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, et al. (2004) Autologous cytokine-induced killer celltherapy in clinical trial phase I is safe inpatients with primary hepatocellular carcinoma. World J Gastroenterol 10: 1146-1151.
20. Haruta I, Yamauchi K, Aruga A, Komatsu T, Hayashi N, et al. (1996) Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. Journal of Immunotherapy With Emphasis on Tumor Immunology: Official Journal of the Society for Biological Therapy 19: 218-223.
21. Kanai T, Monden M, Takeda T, Gotoh M, Sakon M, et al. (1993) Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2. Gan To Kagaku Ryoho 20: 1457-1460.
22. Lafreniere R, Rosenberg SA, (1985) Successful immunotherapy of murine experimental hepaticmetastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45: 3735-3741.
23. Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H, (1995) Hepatocellular carcinoma: surgical resection versus surgicalresection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 15: 543-550.
24. Bruix J, Sherman M, (2005) Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
25. Zhong JH, Li LQ, (2010) Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatol Res 40: 943-953.
26. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, et al. (2009) Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. The British Journal of Surgery 96: 975-981.
27. Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, et al. (2000) Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 88: 1016-1024.
28. Linn YC, Hui KM, (2010) Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 43: 574-575.